Cullen Frost Bankers Inc. Sells 195 Shares of Edwards Lifesciences Co. (NYSE:EW)

Cullen Frost Bankers Inc. lowered its stake in Edwards Lifesciences Co. (NYSE:EW) by 1.1% in the fourth quarter, Holdings Channel reports. The fund owned 18,038 shares of the medical research company’s stock after selling 195 shares during the quarter. Cullen Frost Bankers Inc.’s holdings in Edwards Lifesciences were worth $1,335,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Wellington Management Group LLP lifted its holdings in shares of Edwards Lifesciences by 86.3% in the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after acquiring an additional 14,610,123 shares during the last quarter. State Street Corp boosted its position in Edwards Lifesciences by 1.0% during the 3rd quarter. State Street Corp now owns 26,265,633 shares of the medical research company’s stock worth $1,733,270,000 after buying an additional 256,538 shares during the period. Geode Capital Management LLC boosted its position in Edwards Lifesciences by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company’s stock worth $889,050,000 after buying an additional 284,918 shares during the period. Fisher Asset Management LLC boosted its position in Edwards Lifesciences by 7.7% during the 4th quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company’s stock worth $723,664,000 after buying an additional 696,965 shares during the period. Finally, Jennison Associates LLC acquired a new stake in Edwards Lifesciences during the 4th quarter worth approximately $555,939,000. Institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of the business’s stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the sale, the vice president now owns 23,189 shares in the company, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Steven R. Loranger sold 5,739 shares of the company’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $76.42, for a total transaction of $438,574.38. Following the completion of the sale, the director now owns 60,372 shares of the company’s stock, valued at approximately $4,613,628.24. The trade was a 8.68 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 37,739 shares of company stock worth $2,799,104. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $70.36 on Friday. The company has a fifty day moving average of $72.26 and a 200-day moving average of $70.38. The firm has a market capitalization of $41.50 billion, a P/E ratio of 10.10, a P/E/G ratio of 4.82 and a beta of 1.10. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Analysts Set New Price Targets

EW has been the topic of several recent research reports. Barclays lifted their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. Wolfe Research downgraded shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 12th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $82.00 to $90.00 in a research report on Monday, December 16th. The Goldman Sachs Group lifted their target price on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, December 5th. Finally, Stifel Nicolaus upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and lifted their target price for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Hold” and a consensus price target of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.